Welcome!

News Feed Item

The Pharmaceutical Market: UK

NEW YORK, Nov. 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Pharmaceutical Market: UK

http://www.reportlinker.com/p0203096/The-Pharmaceutical-Market-UK.html#u...

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 1

Snapshot: Strategic Espicom Analysis 2

Snapshot: Key Data Projections3

MACROENVIRONMENT 4

POLITICAL 4

ECONOMIC5

Projections 5

LEGAL6

EU Patent Protection & Intellectual Property Rights 6

Proposal for Unitary Patent 6

EU Supplementary Protection Certificates6

EU Data Exclusivity6

DEMOGRAPHIC 7

Projections 7

Demographic Indicators8

Births 8

Deaths 8

Infant Deaths 8

Life Expectancy at Birth 8

EPIDEMIOLOGY 9

DISEASE BURDEN 9

Leading Causes of Mortality9

DISEASE PREVALENCE10

Communicable Diseases 10

HIV/AIDS 10

Non-Communicable Diseases 11

Cancer 11

Diabetes 11

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12

EU DIRECTIVE12

Cross-Border Healthcare Directive 12

ORGANISATION 12

Performance 12

Structure 13

Department of Health 14

Strategic Health Authorities 14

Primary Care Trusts 14

Acute Trusts 14

NHS Foundation Trusts 14

NHS Care Trusts 15

Ambulance Trusts 15

Care Quality Commission 15

EXPENDITURE 17

Projections 17

NHS Budget 18

Private Healthcare 18

INFRASTRUCTURE 19

Hospital Infrastructure19

Private Hospital Operators19

BMI Healthcare 19

HCA International 19

Netcare 19

NHS Trusts 20

Nuffield Health 20

Partnership Health Group (PHG) 20

Ramsay Healthcare20

Spire Healthcare 20

Ambulatory Infrastructure21

SERVICES 21

Hospital Inpatient Services 21

Outpatient Services22

WORKFORCE 22

Projections 22

Physicians 23

Nurses 23

Dentists 24

Pharmacists 24

REGULATORY AFFAIRS 25

EU REGULATORY AUTHORITY 25

NATIONAL AUTHORITIES 25

MARKETING REGISTRATION 26

EU Marketing Registration26

Centralised Procedure 26

National Procedures 27

IMPORT REGULATIONS 27

Parallel Trade 27

PROMOTION 28

Advertising 28

PRICING & REIMBURSEMENT 29

EU NETWORKING MEETING 29

NM CAPR29

PRICING 29

PPRS Reforms 29

Patient Access Schemes 30

Prescription Charges 31

REIMBURSEMENT 31

DISTRIBUTION CHANNELS 34

EU DIRECTIVE 34

Falsified Medicines Directive34

DRUG WHOLESALING 34

Association of Wholesalers 34

BAPW34

Leading Wholesalers 35

AAH Pharmaceuticals 35

Alliance Healthcare35

DRUG RETAILING 36

Association of Independent Pharmacies 36

Numark36

Association of Community Pharmacies36

NPA 36

Leading Pharmacy Chains 37

Alliance Boots 37

Lloydspharmacy 37

Superdrug 37

MARKET ANALYSIS 38

SIZE 38

Projections 38

Historical Figures 40

Current Structure 41

PRODUCT DEVELOPMENT 49

EU Programmes49

Horizon 2020 49

IMI 49

National Research & Development 49

MANUFACTURING 52

TRADE53

Exports 53

Imports 56

Balance of Trade 60

COMPETITION 61

TRADE ASSOCIATIONS 61

ABPI 61

COMPANY INTELLIGENCE 62

AstraZeneca62

Eisai62

Eli Lilly 62

GlaxoSmithKline 62

MSD63

Novartis 63

Pfizer 64

ProStrakan64

Shire Pharmaceuticals 65

ViiV Healthcare 65

Competitive Strategies65

GLOBAL COMPANY INTELLIGENCE 66

AstraZeneca66

Company Overview 66

Financial Performance66

Product Portfolio 67

R&D Strategy 69

Manufacturing Capabilities 71

Outlook 71

GlaxoSmithKline 72

Company Overview 72

Financial Performance72

Product Portfolio 73

R&D Strategy 75

Manufacturing Capabilities 76

Outlook 76

Shire 77

Company Overview 77

Financial Performance78

Product Portfolio 79

R&D Strategy 80

Manufacturing Capabilities 81

OTC PHARMACEUTICALS 82

REGULATION 82

Marketing Registration 82

Labelling 82

MARKET SIZE 83

COMPETITION 84

Trade Association84

PAGB 84

GENERIC PHARMACEUTICALS 85

REGULATION 85

EU Marketing Registration85

Pricing & Reimbursement 85

Generic Substitution Plans are Scrapped 85

Unbranded Generic Pricing 85

2005 Generics Reimbursement Scheme 86

MARKET SIZE 87

COMPETITION 90

Trade Association90

BGMA90

Company Intelligence 90

Actavis 90

Bristol Laboratories90

Dr Reddy's 91

Kent Pharmaceuticals 91

Pfizer 91

Rosemont Pharmaceuticals 91

Teva Pharmaceuticals 91

Winthrop Pharmaceuticals 92

Wockhardt 92

BIOLOGICS & BIOSIMILARS 93

REGULATION 93

EU Approval Process 93

EU Regulation of Biosimilars 93

EMA Guideline Documents94

Draft Biosimilar Concept Paper94

Biosimilar mAb Guideline 94

Biosimilars Approved in the EU 95

National Regulation 95

NICE Approves First Biosimilar for NHS Use95

PRODUCT DEVELOPMENT 96

Cancer Research 96

Stem Cell Research 96

COMPETITION 97

Trade Association97

BIA 97

Company Intelligence 97

Angel Biotechnology97

Argenta 97

Ark Therapeutics 98

Astex Therapeutics98

BigDNA98

BioFocus 98

Biogen Idec 98

BTG 99

Cellartis99

Convergence Pharmaceuticals 99

FMC BioPolymer 99

ImmuPharma 99

Intercell 99

Lonza 100

NovaBiotics100

Oxford BioMedica100

PolyTherics 100

Silence Therapeutics 101

UCB 101

Competitive Strategies 101

CONCLUSIONS: OPPORTUNITIES & CHALLENGES 103

Strategic Espicom Analysis 103

MACROENVIRONMENT 103

EPIDEMIOLOGY 103

HEALTHCARE103

REGULATORY AFFAIRS104

PRICING & REIMBURSEMENT 104

DISTRIBUTION CHANNELS 105

MARKET 105

COMPETITION 106

OTC PHARMACEUTICALS 106

GENERIC PHARMACEUTICALS106

BIOLOGICS & BIOSIMILARS 106

Radar Analysis 108

SWOT Analysis 108

DIRECTORY 109

GOVERNMENT ORGANISATIONS 109

PHARMACEUTICAL COMPANIES 109

Biologic Companies 109

Generic Companies 109

PHARMACEUTICAL DISTRIBUTORS110

PHARMACY CHAINS 110

TRADE ORGANISATIONS110

List of Tables

Espicom Analysis of the Pharmaceutical Market, 2012 2

Key Data Projections, 2012-2017 3

Political Landscape, 2012 4

Regional Ranking of Projected Economies, 2017 5

Projected Economy, 2012-2017 5

Regional Ranking of Projected Demographics, 2017 7

Projected Demographics, 2012-2017 7

Demographic Indicators, 2002-2009 8

Causes of Death by Country, 2010 9

HIV and AIDS Cases, up to 2010 10

Regional Ranking of Projected Health Expenditure, 2017 17

Projected Health Expenditure, 2012-201717

Inpatient Procedures and Interventions by Type, 2010/11 21

Regional Ranking of Projected Physicians, 2017 22

Projected Physicians, 2012-2017 22

Consultants by Specialty in England, 2008-2010 23

NHS Nurses by Country, 2007-2009 23

Patient Access Schemes in Published Guidance, 2007-2010 30

NICE Appraisals in Development, January 2012 31

Members of BAPW, 2011 34

Celesio's Revenue from Wholesale Activities, 2007-2009 (Euro Millions) 35

Alliance Healthcare's Financial Highlights, 2008-2010 (£ Millions) 35

Regional Ranking of Projected Pharmaceutical Markets, 2017 38

Projected Pharmaceutical Market at Retail Prices, 2012-2017 38

Historical Pharmaceutical Market at Retail Prices, 1995-2011 40

Written Prescriptions, 2006-2010 (Millions) 41

Prescriptions by Value, 2006-2010 (£ Millions) 41

Prescriptions & Cost by Therapeutic Area in the UK, 2010 42

Prescriptions & Cost by Therapeutic Area in England, 2010 43

Top 20 Prescribed Drugs in England by Value, 2010 44

Top 20 Prescribed Drugs in England by Volume, 2010 45

Cost of Pharmaceuticals Issued by Hospital Pharmacies in England, 2003-2010 (£ Millions) 45

Prescriptions & Cost by Therapeutic Area in Wales, 2010 46

Prescriptions & Cost by Therapeutic Area in Scotland, 2010 47

Prescriptions & Cost by Therapeutic Area in Northern Ireland, 201048

Pharmaceutical R&D Expenditure, 1972-2007 (£ Millions) 50

Pharmaceutical Production, 1995-2010 (Euros 000s) 52

Pharmaceutical Exports by Category, 1995-2010 (US$000s) 53

Pharmaceutical Exports by Country/Region, 2010 (US$000s) 55

Pharmaceutical Imports by Category, 1995-2010 (US$000s) 56

Imports of Raw Materials by Country/Region, 2010 (US$000s) 58

Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s) 58

Imports of Medicaments by Country/Region, 2010 (US$000s) 59

Balance of Pharmaceutical Trade, 1995-2010 (US$000s) 60

Full Members of the ABPI, 2011 61

AstraZeneca's Principal Operating Results, 2006-2010 (US$ Million) 66

AstraZeneca's Sales by Geographic Area, 2006-2010 (US$ Million) 67

AstraZeneca's Sales by Leading Products, 2006-2010 (US$ Million)68

AstraZeneca's Recent Product Approvals, 2010-2011 69

AstraZeneca's Major Manufacturing Facilities by Location, 2011 71

GSK's Principal Operating Results, 2006-2010 (£ Million) 73

GSK's Sales by Geographic Area, 2007-2010 (£ Million) 73

GSK's Sales by Leading Products, 2006-2010 (£ Million) 74

GSK's Recent Product Approvals, 2010-2011 75 Shire's Principal Operating Results, 2006-2010 (US$ Million) 78

Shire's Revenue by Business Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Geographic Area, 2006-2010 (US$ Million) 78

Shire's Revenue by Leading Products, 2006-2010 (US$ Million) 79

Shire's Recent Product Approvals, 2010-2011 80

Shire's Major Manufacturing Facilities by Location, 2011 81

OTC Sales at Retail Prices, 2007-2010 (£ Millions) 83

Full Members of PAGB, 2011 84

Prescriptions Written and Dispensed Generically in England by Value, 1996-2010 (£ Millions) 87

Prescriptions Written and Dispensed Generically in England by Volume, 1996-2010 (Millions) 88

Generic Prescribing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 88

Generic Dispensing Rates by Therapeutic Area in England, 2005-2010 (% by Volume) 89

Members of BGMA, 2011 90

Biosimilars Approved in the EU 95

Espicom Analysis of the Pharmaceutical Market, 2012 107

SWOT Analysis of the Pharmaceutical Market, 2012 108

List of Charts

Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail Prices, 2017 39

Regional Comparison of Projected Pharmaceutical Market Share, 2017 39

Historical Pharmaceutical Market at Retail Prices, 1995-201140

Pharmaceutical Exports, 1995-2010 (US$ Billions) 54

Pharmaceutical Exports by Country/Region, 2010 (%) 54

Pharmaceutical Imports, 1995-2010 (US$ Billions) 56

Imports of Pharmaceuticals by Country/Region, 2010 (%) 57

Balance of Pharmaceutical Trade, 1995-2010 (US$ Billions)60

Radar Graph of the Pharmaceutical Market, 2012 108

To order this report:

Pharmaceutical Industry: The Pharmaceutical Market: UK

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams. In his session at 22nd Cloud Expo | DXWorld Expo, Daniel Jones, CTO of EngineerBetter, will answer: How can we improve willpower and decrease technical debt? Is the present bias real? How can we turn it to our advantage? Can you increase a team’s effective IQ? How do DevOps & Product Teams increase empathy, and what impact does empath...
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...